Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.80 |
| ▸ | MAPT | P10636 | 9/20 | 0.73 |
| ▸ | LMNA | P02545 | 5/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.73 |
| ▸ | RAB9A | P51151 | 8/20 | 0.60 |
| ▸ | NPC1 | O15118 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 4/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | CCR6 | P51684 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30848523 | 1.00 | POLB (0.80) | POLBMAPTLMNAKMT2ARAB9A | |
| SCHEMBL1463747 | 1.00 | POLB (0.80) | POLBMAPTLMNAKMT2ARAB9A | |
| SCHEMBL12745805 | 1.00 | POLB (0.80) | POLBMAPTLMNAKMT2ARAB9A | |
| SCHEMBL8291521 | 0.84 | MAPT (1.00) | POLBMAPTLMNAKMT2ARAB9A | |
| SCHEMBL11791420 | 0.84 | MAPT (1.00) | POLBMAPTLMNAKMT2ARAB9A | |
| SCHEMBL3522795 | 0.81 | ALDH1A1 (0.58) | POLBMAPTLMNAKMT2ARAB9A | |
| SCHEMBL7074497 | 0.80 | MEN1 (0.62) | POLBMAPTLMNAKMT2ARAB9A | |
| SCHEMBL27481742 | 0.79 | ALDH1A1 (0.66) | POLBMAPTLMNAKMT2ARAB9A | |
| SCHEMBL8291174 | 0.78 | MAPT (0.86) | POLBMAPTLMNAKMT2ARAB9A | |
| SCHEMBL1581083 | 0.78 | ALDH1A1 (0.55) | POLBMAPTLMNAKMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006231-B2 | Cephalotaxus esters, methods of synthesis, and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006231-B2 | Cephalotaxus esters, methods of synthesis, and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140171416-A1 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2014-06-19 | — | — | US | disclosed |
| US-20140171416-A1 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2014-06-19 | — | — | US | disclosed |
| US-8466142-B2 | Cephalotaxus esters, methods of synthesis, and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2013-06-18 | — | — | US | disclosed |
| US-20110071097-A1 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071097-A1 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-03-24 | — | — | US | disclosed |
| EP-2260041-A2 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | Sloan Kettering Institute For Cancer Research (US) | 2010-12-15 | — | — | EP | disclosed |
| WO-2009148654-A2 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009148654-A2 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071097-A1 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | COASY, CXCR4, CETP | POLB 2023/4885MAPT 3005/4885LMNA 4783/4885 |
| US-20140171416-A1 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | COASY, CXCR4, CETP | POLB 2023/4885MAPT 3005/4885LMNA 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.